The methodology of creating a vaccine against candidiasis




vaccine, methodology, research algorithm, technology


Candidiasis is one of the most common diseases of our time. For many years to treat candidiasis the same antifungal drugs, to which the fungi gradually develop resistance, have been used. One of the ways to solve the problem of effective treatment of candidiasis is to use vaccines, which have a number of significant advantages compared to other antifungal drugs. Currently, there are no vaccines against candidiasis at the pharmaceutical market.

Aim. To substantiate the general concept for creation of a new vaccine based on Candida fungi.

Materials and methods. Development of a new vaccine should be combined on a common methodological approach to pharmaceutical development taking into account the requirements for a dosage form. In order to determine the general concept for creation of a new vaccine the following areas of research have been outlined: development of a new vaccine based on inactivated cells of Candida genus fungi and creation of a new vaccine for the renewal of proteins and polysaccharides of fungi of Candida genus fungi.

Results. To provide the effectiveness and safety of the vaccine all pharmaceutical and technological factors that affect the vaccine should be theoretically and experimentally substantiated. They include the nature and the amount of active substances, technological parameters for preparation and mixing of active substances, the physicochemical and biological properties of active substances and excipients, equipment. In order to provide the therapeutic effectiveness of the vaccine the biopharmaceutical studies to determine antibody titers and efficacy in the prevention and treatment of candidal infection were conducted.

Conclusions. Thus, on the basis of the universal methodological approach to pharmaceutical development the methodology has been substantiated; the plan for experimental studies on creating the solution of the vaccine for injection to prevent and treat candidiasis on the basis of fungal cells of Candida genus has been developed.


Campion, E. W., Kullberg, B. J., Arendrup, M. C. (2015). Invasive Candidiasis. New England Journal of Medicine, 373 (15), 1445–1456. doi:10.1056/nejmra1315399

Antinori, S., Milazzo, L., Sollima, S., Galli, M., Corbellino, M. (2016). Candidemia and invasive candidiasis in adults: A narrative review. European Journal of Internal Medicine, 34, 21–28. doi: 10.1016/j.ejim.2016.06.029.

Tykhonov, O. I., Frolova, O. Ye., Hudzenko, O. P., Barnatovych, S. V. (2015). Social pharmacy in health care, 2 (2), 77–81.

Pappas, P. G., Kauffman, C. A., Andes, D. R. et al. (2016). Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 62:e1.

Cassone, A. (2013). Development of vaccines for Candida albicans: fighting a skilled transformer. Nature Reviews Microbiology, 11 (12), 884–891. doi: 10.1038/nrmicro3156.

Wang, X., Sui, X., Yan, L., Wang, Y., Cao, Y., Jiang, Y. (2015). Vaccines in the treatment of invasive candidiasis. Virulence, 6 (4), 309–315. doi: 10.4161/21505594.2014.983015.

Krasnopol’skii, Yu. M., Borshchevskaia, M. Y. (2009). Farmatsevticheskaia biotekhnolohiia. Tekhnolohiia proizvodstva immunobiolohicheskikh preparatov. Kharkov: NTU «KhPI», 352.

Crommelin, D. J. A., Sindelar, R. D., Meibohm, B. (2013). Pharmaceutical biotechnology: fundamentals and applications. (4th ed.). New York: Springer, 490.





Social medicine and pharmacy: past, present and development prospects